Hexarelin

Hexarelin is a synthetic six-amino-acid growth hormone-releasing peptide (GHRP) and ghrelin receptor agonist. It is one of the most potent GH-releasing peptides studied, and is notable for additional action at the cardiac CD36 receptor.

Hexarelin is the heavy hitter of the older GHRP family. It pushes the pituitary to release a strong GH pulse and also appears in heart-research discussions because of its cardiac receptor binding.

Activates GHS-R1a (ghrelin) receptors on the pituitary to release growth hormone, and binds CD36 on cardiac tissue — the basis for cardioprotection research.

Among the most potent GHS compounds. Massive GH spike potential.

1. Hexarelin
2. GHRH and/or ghrelin receptors in the pituitary
3. Pulsatile growth hormone release
4. Downstream IGF-1, body-composition and recovery endpoints

A plain-English read on how much published evidence currently exists for Hexarelin. These ratings describe the volume and maturity of the literature — not effectiveness, safety, or suitability for any use.

Current limitations: most compounds in this category are studied in preclinical or small-sample settings. Absence of large controlled human trials is the single biggest limitation to keep in mind when reading any summary of Hexarelin.

Lyophilized compounds are supplied as a dry powder. Concentration is simply the total amount in the vial divided by the volume of bacteriostatic water added:

Concentration (mg/mL) = total mg in vial ÷ mL of diluent added

Commonly supplied vial sizes

5mg vial

Worked concentration example

5mg + 2mL BAC water → 2.5mg/mL On U-100 insulin syringe:

• • 4 units = 100mcg

Run your own numbers with the reconstitution calculator — it converts vial size and diluent volume into mg/mL and mcg/mL.

The figures below are reported here descriptively, because they are the values most frequently cited in publicly available research literature and reference material. They are not instructions, not a protocol, and not a recommendation. These compounds are supplied for laboratory research use only and are not approved by the FDA for human consumption.

Commonly cited amounts

100mcg, 2–3× daily subcutaneous

Commonly cited frequency

2–3× daily

Commonly cited study duration

ONLY 2–4 weeks — rapid pituitary desensitization beyond that

Peptides are supplied freeze-dried because peptide bonds degrade far faster in solution than in a dry state. Understanding storage is part of understanding why the powder form exists at all.

• •Lyophilized powder: stored refrigerated, typically stable for months to years.
• •Reconstituted solution: refrigerated at 2–8°C, generally discussed as stable for roughly 30–60 days.
• •Heat and direct light accelerate degradation — vials are kept cool and dark.
• •Reconstituted material is not re-frozen; ice crystal formation disrupts peptide structure.
• •Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what allows multi-day storage after reconstitution.

More detail in the storage & handling guide and how peptide quality is evaluated.

• •Pituitary GH release
• •Cardiac CD36 receptor research
• •Cardioprotection in ischemia models
• •Comparison with GHRP-2, GHRP-6, and Ipamorelin
• •Receptor desensitization studies

Discussed as the most potent GHRP, but also the one most likely to raise cortisol and prolactin compared to Ipamorelin. Community protocols typically cycle it.

“The heaviest hitter of the old-school GHRPs.”

Sometimes paired with a GHRH analog like CJC-1295 No DAC for synergistic GH pulses. Often replaced by Ipamorelin for a cleaner side-effect profile.

Hexarelin is a potent GHRP and ghrelin receptor agonist studied for GH release and cardiac CD36 research. Sold for laboratory research only.